Drug Profile


Alternative Names: Ibutamoren mesilate; Ibutamoren mesylate; L 163191; MK-0677; MK-677

Latest Information Update: 02 Mar 2009

Price : $50

At a glance

  • Originator Merck & Co
  • Class Indoles; Small molecules; Spiro compounds
  • Mechanism of Action Growth hormone releasing factor agonists; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Fibromyalgia; Muscular atrophy
  • Discontinued Alzheimer's disease; Fracture; Postmenopausal osteoporosis; Somatotropin deficiency

Most Recent Events

  • 18 Nov 2008 Final efficacy and safety data from a phase II trial for Alzheimer's disease released by Merck
  • 18 Nov 2008 Discontinued - Phase-II for Alzheimer's disease in USA (PO)
  • 01 Aug 2007 No development reported - Phase-II for Muscle wasting in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top